A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
Latest Information Update: 09 Oct 2023
At a glance
- Drugs LUT 014 (Primary)
- Indications Acneiform eruptions
- Focus Therapeutic Use
- Sponsors Lutris Pharma
- 29 Dec 2022 Planned End Date changed from 1 Sep 2023 to 1 May 2024.
- 29 Dec 2022 Planned primary completion date changed from 1 Jun 2023 to 1 Mar 2024.
- 06 Sep 2022 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.